Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis

Circ J. 2003 Oct;67(10):898-900. doi: 10.1253/circj.67.898.

Abstract

Excretion in the urine is an important pathway for the elimination of nifekalant hydrochloride (NIF), a novel class III antiarrhythmic agent. Three patients with renal failure were undergoing hemodialysis and receiving NIF for the prevention of ischemia-induced ventricular tachyarrhythmia. Because NIF is not dialyzed, dose adjustment at relatively low concentrations was required, with monitoring of the QT interval.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Arrhythmia Agents / administration & dosage*
  • Anti-Arrhythmia Agents / pharmacokinetics
  • Diabetic Nephropathies / complications
  • Diabetic Nephropathies / therapy
  • Drug Monitoring*
  • Electrocardiography
  • Humans
  • Injections, Intravenous
  • Male
  • Myocardial Ischemia / complications
  • Pyrimidinones / administration & dosage*
  • Pyrimidinones / pharmacokinetics
  • Renal Dialysis*
  • Renal Insufficiency / complications
  • Renal Insufficiency / therapy
  • Tachycardia, Ventricular / etiology
  • Tachycardia, Ventricular / prevention & control*

Substances

  • Anti-Arrhythmia Agents
  • Pyrimidinones
  • nifekalant